Maggot debridement therapy in critical limb ischaemia: a case study

Area of Science:

• Vascular Surgery
• Wound Healing
• Biotherapy

Background:

• Critical limb ischaemia (CLI) management typically involves revascularisation.
• Alternative treatments are needed for CLI ulcers, where maggot debridement therapy (MDT) was historically contraindicated.
• Advancements in revascularisation strategies necessitate re-evaluating MDT for CLI.

Purpose of the Study:

• To assess the efficacy of maggot debridement therapy (MDT) in critical limb ischaemia (CLI) patients.
• To evaluate changes in skin perfusion pressure (SPP) following MDT in CLI ulcers.
• To determine optimal conditions for MDT in CLI wound healing.

Main Methods:

• Retrospective review of five CLI cases treated with MDT between 2013-2017.
• Evaluation of skin perfusion pressure (SPP) changes pre- and post-MDT.
• Assessment of necrotic tissue proportion (NT 1+ to NT 4+) and exposed necrotic bone.

Main Results:

• Increased SPP observed in 62.5% of MDT cycles when necrotic tissue was >50% and no exposed bone.
• Decreased SPP noted in 37.5% of cycles with <25% necrotic tissue and/or exposed bone.
• Wound healing correlated with increased SPP.

Conclusions:

• Maggot debridement therapy (MDT) can be effective for critical limb ischaemia (CLI) with significant necrosis.
• Optimal outcomes with MDT in CLI require necrotic tissue grade > NT 3+ and absence of exposed necrotic bone.
• MDT shows potential as an alternative treatment for specific CLI ulcer presentations.